Navigation Links
Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
Date:6/12/2013

FARMINGDALE, N.Y., June 12, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery,  wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced today that is has received a new U.S. patent on the Company's medical device products. The patent describes a means to control the output of various powered surgical devices such that power can be applied only at times where the tool is translated forward in the operative site and not at other times. By limiting power on to only the time required, tissue heating is reduced thereby improving procedure outcome and enhancing safety along with surgeon ergonomics. This action does not require the surgeon to activate switches or other mechanical means so that the action is transparent to the user. 

To date this year, six patents have been issued to Misonix, many of which apply to the Company's ultrasonic platform in general and to its BoneScalpel™ product.

Michael A. McManus, Jr., President and CEO of Misonix stated, "Misonix continues to grow and protect its core technology through continued intellectual property development and patent submissions. We believe our unique application of Ultrasound technology is one of our great assets which will continue to create growth opportunities and value going forward."

About Misonix:Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Private Securities Litigation Reform Act of 1995With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on Form 8 K.  The Company disclaims any obligation to update its forward looking relationships.Misonix Contact:

 Investor Relations Contact:Richard Zaremba

 Joe Diaz, Lytham Partners631-694-9555

 602-889-9700invest@misonix.com

 mson@lythampartners.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Announces Appointment of Three Members to Its Executive Team
2. Ohr Pharmaceutical Announces Approval for Listing on NASDAQ
3. IRIDEX Announces Automatic Conversion of Series A Preferred Stock to Common Stock
4. River Vision Announces Receipt of Orphan Drug Designation
5. CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
6. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
7. Affiliate Retailer of Health and Wellness Products Announces New Online Store at YouNeedIt.biz
8. W.K. Kellogg Foundation announces Mission Driven Investment in SeeChange Health
9. C&J Industries Announces Additional Expansion
10. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
11. TNI BioTech, Inc. Announces Mandatory Exchange of Common Stock Certificates CUSIP Number 872608104 for New Stock Certificates with Active CUSIP 872608203
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... and technology platform for value-based precision medicine, ... multi-year collaboration with Novartis Pharmaceuticals Corporation to ... breast cancer patients. As part ... the previous announced collaboration entered into January ...
(Date:3/27/2017)... 2017 Arena Pharmaceuticals, Inc. (NASDAQ: ... small molecule drugs across multiple therapeutic areas, today announced that ... will present a corporate update at the 16th Annual Needham ... conference will take place April 4-5, 2017 at the Westin ... , NY.  A live audio webcast of ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, a ... year in a row; they are the recipient of the prestigious “Best Overall ... on the award at Design Connections 2017. Top A&D professionals from leading firms, ...
(Date:3/27/2017)... Switzerland (PRWEB) , ... March 27, 2017 , ... ... food industry. Conventional sodium testing methods are complicated and require expert user knowledge. ... a new analytical method dedicated to the simplified, yet highly accurate, determination of ...
(Date:3/27/2017)... Clearwater, Fla. (PRWEB) , ... March 27, 2017 , ... ... (1) and the number of homeowners utilizing DIY and unlicensed contractors for renovations is ... bathroom remodel or replacement project in 2015, and of those, 42% failed to use ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... contaminated soil, dredged material, and hazardous and non-hazardous materials announced today the acquisition ... This acquisition will add four additional processing facilities and a vast array ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management ... . The annual awards, now in their 12th year, are among the most prestigious ... , In 2016, the awards were retooled to recognize achievements in both large budget ...
Breaking Medicine News(10 mins):